Immunostimulatory bacterial antigen–armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapyEleni Panagioti, Evanthia Galanis|Journal of Clinical Investigation|2021Cited by 61
Antigen presentation deficiency, mesenchymal differentiation, and resistance to immunotherapy in the murine syngeneic CT2A tumor modelJ. Bryan Iorgulescu, David A. Reardon, Ryuhjin Ahn et al.|Frontiers in Immunology|2023Cited by 23